Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/13687
Title: Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
Authors: David A. Reardon
James J. Vredenburgh
Annick Desjardins
Katherine B. Peters
Sith Sathornsumetee
Stevie Threatt
John H. Sampson
James E. Herndon
April Coan
Frances McSherry
Jeremy N. Rich
Roger E. McLendon
Steven Zhang
Henry S. Friedman
Dana-Farber Cancer Institute
Duke University School of Medicine
Mahidol University
Cleveland Clinic Foundation
Bristol-Myers Squibb
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine;Neuroscience
Issue Date: 1-Jul-2012
Citation: Journal of Neuro-Oncology. Vol.108, No.3 (2012), 499-506
Abstract: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an e pidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma patients. Once daily dasatinib was escalated in successive cohorts while erlotinib was administered daily at established doses based on concurrent CYP3A-inducing anticonvulsant (EIAEDS) use. Dasatinib pharmacokinetic analyzes were performed. Forty-seven patients enrolled including 37 (79 %) with grade IV and 10 (21 %) with grade III malignant glioma. Thirty patients (64 %) were at Csecond recurrence, while 27 (57 %) had received prior bevacizumab. The dasatinib MTD was 180 mg when combined with either 150 mg of erlotinib for patients not on EIAEDs, or 450 mg of erlotinib for patients on EIAEDs. The most common DLTs were diarrhea and fatigue, while most adverse events were grade 2. Pharmacokinetic data suggests that dasatinib exposure increased with increased dasatinib dose and concurrent erlotinib administration, while concurrent EIAED use diminished dasatinib exposure. No radiographic responses were observed, and only one patient (2 %) remained progression-free at 6 months. We demonstrate that dasatinib plus erlotinib can be safely co-administered on a continuous, daily dosing schedule with erlotinib, and established the recommended dose level of this combination. © 2012 Springer Science+Business Media, LLC.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864042721&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/13687
ISSN: 15737373
0167594X
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.